Aprogen Biologics Inc. (KRX: 003060)
South Korea
· Delayed Price · Currency is KRW
720.00
-1.00 (-0.14%)
Nov 18, 2024, 11:34 AM KST
Aprogen Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Other Revenue | -0 | - | - | - | 0 | -0 | Upgrade
|
Revenue | 73,635 | 87,364 | 65,190 | 56,482 | 53,320 | 50,904 | Upgrade
|
Revenue Growth (YoY) | -5.14% | 34.01% | 15.42% | 5.93% | 4.75% | 12.13% | Upgrade
|
Cost of Revenue | 80,342 | 99,337 | 39,380 | 31,607 | 30,515 | 30,911 | Upgrade
|
Gross Profit | -6,707 | -11,974 | 25,810 | 24,875 | 22,805 | 19,992 | Upgrade
|
Selling, General & Admin | 28,440 | 29,789 | 28,914 | 25,947 | 23,579 | 21,093 | Upgrade
|
Research & Development | 20,437 | 15,000 | 2,187 | 1,735 | 697.7 | 336.12 | Upgrade
|
Other Operating Expenses | 352 | 357.6 | 365.27 | 416.95 | 592.21 | 343.19 | Upgrade
|
Operating Expenses | 71,685 | 58,716 | 30,015 | 28,850 | 23,885 | 21,923 | Upgrade
|
Operating Income | -78,392 | -70,690 | -4,204 | -3,975 | -1,081 | -1,930 | Upgrade
|
Interest Expense | -4,408 | -3,668 | -274.41 | -31.14 | -49.06 | -3,325 | Upgrade
|
Interest & Investment Income | 3,836 | 4,488 | 16,645 | 13,587 | 9,176 | 3,400 | Upgrade
|
Earnings From Equity Investments | 86,834 | 79,786 | 94.73 | 352.2 | 1,510 | 4,674 | Upgrade
|
Currency Exchange Gain (Loss) | 119 | -6.22 | 33.16 | 12.72 | -26.11 | -15.49 | Upgrade
|
Other Non Operating Income (Expenses) | -2,879 | 564.26 | 209.78 | 347.85 | 423.69 | 45,486 | Upgrade
|
EBT Excluding Unusual Items | 5,109 | 10,474 | 12,504 | 10,294 | 9,953 | 48,289 | Upgrade
|
Gain (Loss) on Sale of Investments | 14,698 | 29,950 | 2,638 | 1,623 | 6,341 | -50,265 | Upgrade
|
Gain (Loss) on Sale of Assets | -151,526 | -151,537 | 3.1 | 53.08 | 593.48 | 0.89 | Upgrade
|
Asset Writedown | -2,271 | -2,271 | -264.15 | -2,134 | -241.5 | -553.33 | Upgrade
|
Other Unusual Items | - | - | -1.04 | -4.76 | -2.67 | -529.25 | Upgrade
|
Pretax Income | -133,989 | -113,383 | 14,881 | 9,831 | 16,644 | -3,057 | Upgrade
|
Income Tax Expense | 1,870 | 1,947 | 1,260 | 679.69 | -2,274 | 409.26 | Upgrade
|
Earnings From Continuing Operations | -135,860 | -115,330 | 13,621 | 9,151 | 18,918 | -3,467 | Upgrade
|
Minority Interest in Earnings | 4,716 | -2,940 | -981.32 | -1,048 | -7,665 | -4,848 | Upgrade
|
Net Income | -131,144 | -118,270 | 12,639 | 8,103 | 11,253 | -8,315 | Upgrade
|
Net Income to Common | -131,144 | -118,270 | 12,639 | 8,103 | 11,253 | -8,315 | Upgrade
|
Net Income Growth | - | - | 55.99% | -28.00% | - | - | Upgrade
|
Shares Outstanding (Basic) | 66 | 63 | 40 | 40 | 32 | 16 | Upgrade
|
Shares Outstanding (Diluted) | 66 | 63 | 40 | 40 | 32 | 16 | Upgrade
|
Shares Change (YoY) | 30.86% | 56.07% | 1.42% | 25.52% | 94.17% | 66.31% | Upgrade
|
EPS (Basic) | -1977.60 | -1874.81 | 312.69 | 203.29 | 354.38 | -508.42 | Upgrade
|
EPS (Diluted) | -1977.60 | -1874.81 | 310.00 | 200.00 | 350.00 | -510.00 | Upgrade
|
EPS Growth | - | - | 55.00% | -42.86% | - | - | Upgrade
|
Free Cash Flow | -45,232 | -61,739 | 24,444 | -7,023 | 7,112 | -1,416 | Upgrade
|
Free Cash Flow Per Share | -682.09 | -978.68 | 604.74 | -176.20 | 223.97 | -86.60 | Upgrade
|
Gross Margin | -9.11% | -13.71% | 39.59% | 44.04% | 42.77% | 39.27% | Upgrade
|
Operating Margin | -106.46% | -80.91% | -6.45% | -7.04% | -2.03% | -3.79% | Upgrade
|
Profit Margin | -178.10% | -135.38% | 19.39% | 14.35% | 21.10% | -16.33% | Upgrade
|
Free Cash Flow Margin | -61.43% | -70.67% | 37.50% | -12.43% | 13.34% | -2.78% | Upgrade
|
EBITDA | -59,089 | -49,292 | -1,800 | -1,903 | 851.33 | -269.75 | Upgrade
|
EBITDA Margin | -80.25% | -56.42% | -2.76% | -3.37% | 1.60% | -0.53% | Upgrade
|
D&A For EBITDA | 19,303 | 21,398 | 2,404 | 2,072 | 1,932 | 1,661 | Upgrade
|
EBIT | -78,392 | -70,690 | -4,204 | -3,975 | -1,081 | -1,930 | Upgrade
|
EBIT Margin | -106.46% | -80.91% | -6.45% | -7.04% | -2.03% | -3.79% | Upgrade
|
Effective Tax Rate | - | - | 8.47% | 6.91% | - | - | Upgrade
|
Advertising Expenses | - | 740.04 | 1,371 | 7,800 | 4,343 | 4,462 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.